Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy (TT) or chemotherapy (CT)

被引：0
|
作者：
Germani, Marco Maria
Moretto, Roberto
Montana, Javier Ros
Intini, Rossana
Ghelardi, Filippo
Vetere, Guglielmo
Toledo, Rodrigo De Almeida
Bergamo, Francesca
Randon, Giovanni
Elez, Elena
Lonardi, Sara
Oldani, Simone
Giordano, Mirella
Rossini, Daniele
Bravo, Walter Ferrari
Ricagno, Gianmarco
Ugolini, Paola Vignali Clara
Fontanini, Gabriella
Cremolini, Chiara
机构：
[1] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[2] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[3] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[4] Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[5] IRCCS, Dept Oncol, Med Oncol 1, Veneto Inst Oncol IOV, Padua, Italy
[6] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol, Milan, Italy
[7] Vall dHebron Univ Hosp, Barcelona, Spain
[8] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[9] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3569
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.
    Kopetz, Scott
    Murphy, Danielle A.
    Pu, Jie
    Ciardiello, Fortunato
    Desai, Jayesh
    Grothey, Axel
    Van Cutsem, Eric
    Wasan, Harpreet Singh
    Yaeger, Rona
    Yoshino, Takayuki
    Donahue, Amber C.
    Golden, Adele
    Gollerkeri, Ashwin
    Zhu, Zhou
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Prognostic impact of BRAF V600E mutation in patients with non-metastatic colorectal cancer with microsatellite instability: A systematic review and meta-analysis.
    Manthravadi, Sashidhar
    Sun, Weijing
    Saeed, Anwaar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report
    Zhang, Qun
    Li, Li
    Qian, Xiaoping
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [34] BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.
    Sorich, Michael
    Rowland, Andrew
    Dias, Mafalda
    McKinnon, Ross Allan
    Kichenadasse, Ganessan
    Wiese, Michael
    Karapetis, Christos Stelios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
    Nasca, Vincenzo
    Zhao, Joseph
    Ros, Javier
    Lonardi, Sara
    Zwart, Koen
    Cohen, Romain
    Fakih, Marwan
    Jayachandran, Priya
    Roodhart, Jeanine M. L.
    Derksen, Jeroen
    Intini, Rossana
    Bergamo, Francesca
    Mazzoli, Giacomo
    Ghelardi, Filippo
    Ligero, Marta
    Jonnagaddala, Jitendra
    Hawkins, Nicholas
    Ward, Robyn L.
    Wankhede, Durgesh
    Brenner, Hermann
    Hoffmeister, Michael
    Vitellaro, Marco
    Salvatore, Lisa
    Gallois, Claire
    Laurent-Puig, Pierre
    Cremolini, Chiara
    Overman, Michael J.
    Taieb, Julien
    Tougeron, David
    Andre, Thierry
    Kather, Jakob Nikolas
    Sundar, Raghav
    Carmona, Javier
    Elez, Elena
    Koopman, Miriam
    Pietrantonio, Filippo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [36] BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
    Chen Mao
    Ru-Yan Liao
    Li-Xin Qiu
    Xi-Wen Wang
    Hong Ding
    Qing Chen
    Molecular Biology Reports, 2011, 38 : 2219 - 2223
  • [37] BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
    Mao, Chen
    Liao, Ru-Yan
    Qiu, Li-Xin
    Wang, Xi-Wen
    Ding, Hong
    Chen, Qing
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (04) : 2219 - 2223
  • [38] Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
    Ambrosini, M.
    Tougeron, D.
    Modest, P.
    Guimbaud, R.
    Kopetz, S.
    Decraecker, M.
    Sclafani, F.
    Coutzac, C.
    Lievre, A.
    Alouani, E. L.
    Marmorino, F.
    Pernot, S.
    Sinicrope, A.
    Elez Fernandez, E.
    Germani, M. M.
    Pietrantonio, F.
    Lonardi, S.
    Parent, P.
    Gallois, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S32 - S32
  • [39] BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
    Cremolini, C.
    Loupakis, F.
    Perrone, G.
    Ruzzo, A.
    Rulli, E.
    Bencardino, K.
    Vincenzi, B.
    Salvatore, L.
    Graziano, F.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 356 - 357
  • [40] BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (mCRC) PATIENTS
    Cremolini, C.
    Loupakis, F.
    Perrone, G.
    Ruzzo, A.
    Rulli, E.
    Garavaglia, D.
    Bencardino, K.
    Fornaro, L.
    Vincenzi, B.
    Stasi, I
    Masi, G.
    Baldi, G.
    Floriani, I
    Graziano, F.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 8 - 8
12345